Skip to content
Screener

MapLight Therapeutics, Inc. MPLT Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$152.27B+14.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$639.97B+60.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.41B+18.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$4.02B+13.2%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
LBR
LB Pharmaceuticals IncLBRX
$389.92M—

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M—
Total debt$5.6M—
Total equity$399.8M+285%
Total assets$418.8M—

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K—
Free cash flow-$51.2M—

Valuation

See full
Market cap$602.19M-13.2%

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity0×—
Current ratio22.9×—

Where this comes from

Calculated from MapLight Therapeutics, Inc.’s reported figures.

$862.7Mmarket cap+$5.6Mtotal debt−$55.7Mcash and equivalents=$812.61M

The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:25 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224129

FAQ

What is MapLight Therapeutics, Inc.'s enterprise value?
MapLight Therapeutics, Inc. (MPLT) reported enterprise value of $812.61M in Q1 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about MapLight Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude